Immunotherapy Rechallenge After Checkpoint Inhibitor Induced Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review

IF 4.3 3区 材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC
Dorien Geusens , Daan Dierickx , Saskia Carton , Eric Van Cutsem , Jeroen Dekervel
{"title":"Immunotherapy Rechallenge After Checkpoint Inhibitor Induced Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review","authors":"Dorien Geusens ,&nbsp;Daan Dierickx ,&nbsp;Saskia Carton ,&nbsp;Eric Van Cutsem ,&nbsp;Jeroen Dekervel","doi":"10.1016/j.clcc.2024.01.005","DOIUrl":null,"url":null,"abstract":"<div><p></p><ul><li><span>•</span><span><p>As there are increasingly more indications for immune checkpoint inhibitors (ICI), immune related adverse events will also become more prevalent. ICI induced haemophagocytic lymphohistiocytosis (HLH) has been described in case reports and pharmacovigilance database reviews. Literature regarding rechallenge of ICI after resolution of HLH is limited to a few cases.</p></span></li><li><span>•</span><span><p>With this case report, we want to highlight the need for early diagnosis and treatment. We also showed that ICI may be rechallenged safely, provided close monitoring and discussion with the patient.</p></span></li><li><span>•</span><span><p>This article might impact on clinical practice by increasing awareness about ICI induced HLH and contributing to the body of literature regarding this topic.</p></span></li></ul></div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1533002824000057","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0

Abstract

  • As there are increasingly more indications for immune checkpoint inhibitors (ICI), immune related adverse events will also become more prevalent. ICI induced haemophagocytic lymphohistiocytosis (HLH) has been described in case reports and pharmacovigilance database reviews. Literature regarding rechallenge of ICI after resolution of HLH is limited to a few cases.

  • With this case report, we want to highlight the need for early diagnosis and treatment. We also showed that ICI may be rechallenged safely, provided close monitoring and discussion with the patient.

  • This article might impact on clinical practice by increasing awareness about ICI induced HLH and contributing to the body of literature regarding this topic.

检查点抑制剂诱发嗜血细胞淋巴组织细胞增多症后的免疫疗法再挑战:病例报告与文献综述
免疫检查点抑制剂(ICI)在(结直肠)癌的治疗中正变得越来越重要。嗜血细胞性淋巴组织细胞增多症(HLH)涉及免疫过度激活,是免疫疗法的一种罕见但危及生命的不良反应,而且难以诊断。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.20
自引率
4.30%
发文量
567
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信